Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

10-Q - RECORDATI: PUBLICATION OF THE INTERIM REPORT FIRST HALF (AS AT 30.06.2025)

Company: Recordati Industria Chimica e Farmaceutica Date: 2025-07-31 Language: English Register to download

Loading document preview...

Document Preview Not Available

The file type (.pdf) cannot be displayed directly here.

Open Original File

Error loading document preview. Please try the 'Open Original File' link.

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

![](_page_0_Picture_0.jpeg)

![](_page_0_Picture_1.jpeg)

## **RECORDATI: PUBLICATION OF THE INTERIM REPORT FIRST HALF (AS AT 30.06.2025)**

*Milan, 31st July 2025 –* Please be informed that the **Interim Report First Half as at 30th June 2025**, approved on 29th July 2025 by the Board of Directors, as per the press release issued on the same date, to which reference is made, is available to the public, together with **the Independent Auditors' Report on the interim consolidated financial statements as at 30th June 2025**, as of today, at the Company's registered office, on the [Company's website](https://recordati.com/investors-presentations-and-reports/) and on the "[1INFO](http://www.1info.it/)" storage mechanism.

*[Recordati](http://www.recordati.com/) is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,450 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of "unlocking the full potential of life" aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.* 

## **Investor Relations**

Eugenia Litz +44 7824 394 750 Eugenia.Litz@recordati.com Gianluca Saletta +39 348 979 4876 saletta.g@recordati.it

## **Media Relations**

ICR Healthcare US: Alexis Feinberg +1 203 939 2225 [Alexis.feinberg@icrhealthcare.com](mailto:Alexis.feinberg@icrhealthcare.com) UK, Europe & Rest of World: Jessica Hodgson +44 7561 424 788 [jessica.hodgson@icrhealthcare.com](mailto:jessica.hodgson@icrhealthcare.com)

## **RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Registered Office Via Matteo Civitali, 1 20148 Milano, Italy Tel. +39 02 487871 Fax +39 02 40073747 www.recordati.com

Share Capital € 26.140.644,50 fully paid-up Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150 Tax Code/VAT No. 00748210150 Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.àr.l

Unlock Europe's Largest Financial Database—Free

Get instant access to over 2.8M filings from 8,970 companies across 44 markets. No cost. No hassle. Just results.

Save hours with instant data access
Trusted by leading financial institutions
Free forever—no strings attached

Or sign up with

Google Microsoft

Or log in with

Google Microsoft

This premium feature is designed for professionals. Upgrade your plan to gain immediate access and enhance your research capabilities.

Upgrade Now